- A new pre-print describes a general computational method for designing proteins that self-assemble into 3-D macroscopic crystals (>100 µm) with atomic-level accuracy, potentially enabling programmable structural biomaterials (https://www.biorxiv.org/content/10.1101/2022.11.18.517014v1).  
- OpenFold, an open-source re-implementation and re-training of AlphaFold2, has been released; the paper claims it offers new insights into the model’s learning mechanisms and generalization capacity (https://www.biorxiv.org/content/10.1101/2022.11.20.517210v1).  
- Discussion of U.S. gene-therapy pricing cited Luxturna at $425 k per eye, Zolgensma at $2.1 M, Zynteglo at $2.8 M, Skysona at $3 M, and Hemgenix at $3.5 M, prompting debate over whether these treatments are curative or merely palliative.  
- Participants speculated that CodexDNA’s rebranding to “Telesis” may be a response to the ongoing trademark lawsuit filed by Codexis against CodexDNA.  
- nmz787 proposed a “DNA typewriter” concept: using electrostatic or MEMS-actuated enzyme-coated cantilevers to expose or hide restriction/modification enzymes as DNA is electrophoresed past, achieving single-base-level molecular surgery without full DNA synthesis.  
- The same discussion revived a 1998 paper on electrostatic manipulation of DNA via optical tweezers, debating whether modern 4 k LCD spatial light modulators or high-resolution galvanometers could achieve the nanometer-scale control needed for enzymatic precision editing.